JP2018520201A - Ｔｇｆベーター受容体アンタゴニスト - Google Patents

Ｔｇｆベーター受容体アンタゴニスト Download PDF

Info

Publication number
JP2018520201A
JP2018520201A JP2018503142A JP2018503142A JP2018520201A JP 2018520201 A JP2018520201 A JP 2018520201A JP 2018503142 A JP2018503142 A JP 2018503142A JP 2018503142 A JP2018503142 A JP 2018503142A JP 2018520201 A JP2018520201 A JP 2018520201A
Authority
JP
Japan
Prior art keywords
pyrrolo
pyridin
amino
triazin
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018503142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520201A5 (OSRAM
Inventor
ラルグディ・エス・ハリクリシュナン
ブライアン・イー・フィンク
ロバート・エム・ボルジレリ
ゴピキシャン・トヌクヌル
ハシブル・ラーマン
ジャヤクマール・サンカラ・ウォリアー
バラジ・セシャドリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2018520201A publication Critical patent/JP2018520201A/ja
Publication of JP2018520201A5 publication Critical patent/JP2018520201A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018503142A 2015-07-23 2016-07-21 Ｔｇｆベーター受容体アンタゴニスト Pending JP2018520201A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562195854P 2015-07-23 2015-07-23
US62/195,854 2015-07-23
PCT/US2016/043252 WO2017015425A1 (en) 2015-07-23 2016-07-21 Tgf beta receptor antagonists

Publications (2)

Publication Number Publication Date
JP2018520201A true JP2018520201A (ja) 2018-07-26
JP2018520201A5 JP2018520201A5 (OSRAM) 2019-08-15

Family

ID=56609944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018503142A Pending JP2018520201A (ja) 2015-07-23 2016-07-21 Ｔｇｆベーター受容体アンタゴニスト

Country Status (6)

Country Link
US (1) US10336761B2 (OSRAM)
EP (1) EP3325484A1 (OSRAM)
JP (1) JP2018520201A (OSRAM)
KR (1) KR20180032611A (OSRAM)
CN (1) CN108026105B (OSRAM)
WO (1) WO2017015425A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10221191B2 (en) 2015-12-22 2019-03-05 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
AU2018355531B2 (en) * 2017-10-26 2021-10-14 Southern Research Institute Oxadiazoles and thiadiazoles as TGF-beta inhibitors
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US12102626B2 (en) 2018-12-27 2024-10-01 Nexys Therapeutics, Inc. (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer
CN111825675B (zh) * 2019-04-15 2023-08-01 武汉朗来科技发展有限公司 Rock抑制剂及其制备方法和用途
CN112694477B (zh) * 2019-10-22 2024-02-06 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物，包含其的药物组合物，其制备方法及其用途
CN114728965B (zh) * 2020-01-21 2024-05-28 四川科伦博泰生物医药股份有限公司 吡啶并杂环类化合物、其制备方法及用途
CN113620956B (zh) * 2020-05-06 2023-06-13 赛诺哈勃药业（成都）有限公司 转化生长因子受体拮抗剂、其制备方法和应用
KR20250007533A (ko) * 2022-04-08 2025-01-14 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, ras질환 및 섬유성 질환의 치료를 위한 ras 슈퍼패밀리 단백질과 상호작용하는 화합물
MA71454A (fr) * 2022-07-14 2025-04-30 Biogen Ma Inc. Inhibiteurs de tyrosine kinase 2 et leurs utilisations
CN121002022A (zh) * 2023-01-19 2025-11-21 斯基霍克疗法公司 可用于调节剪接的组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501260A (ja) * 2002-09-04 2006-01-12 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP2006521398A (ja) * 2003-03-28 2006-09-21 サイオス・インコーポレーテツド ＴＧＦβの二−環式ピリミジン阻害剤
JP2014511390A (ja) * 2011-03-09 2014-05-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリド［２，３−ｂ］ピラジン誘導体およびそれらの治療的使用
JP2015518010A (ja) * 2012-05-31 2015-06-25 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ ピロロ［２，１−ｆ］［１，２，４］トリアジン系化合物、その製造方法および用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501260A (ja) * 2002-09-04 2006-01-12 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP2006521398A (ja) * 2003-03-28 2006-09-21 サイオス・インコーポレーテツド ＴＧＦβの二−環式ピリミジン阻害剤
JP2014511390A (ja) * 2011-03-09 2014-05-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリド［２，３−ｂ］ピラジン誘導体およびそれらの治療的使用
JP2015518010A (ja) * 2012-05-31 2015-06-25 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ ピロロ［２，１−ｆ］［１，２，４］トリアジン系化合物、その製造方法および用途

Also Published As

Publication number Publication date
CN108026105B (zh) 2020-10-16
CN108026105A (zh) 2018-05-11
WO2017015425A1 (en) 2017-01-26
KR20180032611A (ko) 2018-03-30
EP3325484A1 (en) 2018-05-30
US10336761B2 (en) 2019-07-02
US20180215761A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
JP7579789B2 (ja) 免疫調節剤、組成物およびその使用方法
JP2018520201A (ja) Ｔｇｆベーター受容体アンタゴニスト
TWI820081B (zh) Ｃｂｌ-ｂ抑制劑及其使用方法
CN114450271B (zh) 用于Cbl-b抑制的脲类、氨基类和取代的杂芳基类化合物
KR102583317B1 (ko) Malt1 억제제로서의 피라졸 유도체
TWI794297B (zh) 化合物用於製備與第二抗-呼吸道融合性病毒試劑組合使用以治療呼吸道細胞融合病毒感染的藥物之用途及醫藥組合物
JP6447660B2 (ja) 第ＸＩａ因子阻害剤としての新規ピリジノンおよびピリミジノン誘導体
US9708316B2 (en) TGFβR antagonists
CA3141134A1 (en) Thiadiazolyl derivatives as dna polymerase theta inhibitors
JP2022516401A (ja) Ｉｒａｋ分解剤およびそれらの使用
AU2013331496A1 (en) Methylene linked quinolinyl modulators of ROR-gamma-t
JP2023538060A (ja) 二環化合物、それを含む組成物、及びそれらの使用
JP2022523074A (ja) 化合物及びその使用
JP2019512482A (ja) Ｗｄｒ５タンパク質−タンパク質結合の阻害剤
EA029473B1 (ru) Применение ингибиторов pi3k для лечения острой и церебральной малярии
AU2019200726A1 (en) Methylene linked quinolinyl modulators of ROR-gamma-T
JP2023544789A (ja) Ｍｒｇｘ２アンタゴニスト
JP2018528951A (ja) ＴＧＦβ受容体アンタゴニスト
US20190292179A1 (en) TGF Beta RECEPTOR ANTAGONISTS
KR20210100612A (ko) 시클로알칸-1,3-디아민 유도체
JP2025514670A (ja) ＨＰＫ１阻害剤としてのピリド［３，２－ｄ］ピリミジン
WO2017019757A1 (en) Tgf beta receptor antagonists
TW202448420A (zh) 用於減弱bhlh轉錄因子之myc原癌基因家族之c-myc或n-myc蛋白質的哺乳類轉譯之化合物、組合物及方法
TW202434599A (zh) 造血前驅細胞激酶1之吡啶酮及嘧啶酮抑制劑

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190705

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200609

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210112